MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,291K
Free Cash flow
-$29,632K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Proceeds from issuance of common...
Accounts payable
Others
Negative Cash Flow Breakdown
Net loss
Purchases of investments
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-35,037
-22,969
-20,555
-23,342
Stock-based compensation expense
1,806
1,916
1,429
1,582
Depreciation expense
51
49
49
50
Net amortization of premiums and discounts on investments
226
346
692
50
Amortization of debt discount
-
-
0
0
Other
-10
-84
-13
-47
Prepaid expenses and other current assets
-150
1,947
-297
-2,656
Decrease in other assets
-
-
0
0
Decrease in operating lease right-of-use asset
-
-
-275
-267
Decrease in other long-term liabilities
-
-
0
0
Accounts payable
4,810
-1,868
-564
-1,276
Accrued expenses
-1,268
-346
4,243
4,923
Decrease in operating lease liabilities
-
-
-416
-407
Operating right-of-use assets and operating lease liabilities, net
-78
144
-
-
Net cash used in operating activities
-29,626
-25,571
-15,921
-15,550
Purchases of property and equipment
6
6
7
-
Purchases of investments
8,698
10,726
90,022
17,841
Proceeds from sales and maturities of investments
26,964
33,187
32,884
37,479
Net cash provided by investing activities
18,260
22,455
-57,145
19,638
Proceeds from issuance of common stock, net
9,075
-
74,575
2,851
Repayment of short-term borrowings
-
-
0
0
Repayment of long-term borrowings
-
-
0
0
Net cash provided by financing activities
9,075
-
74,575
2,851
Net (decrease) increase in cash, cash equivalents, and restricted cash
-2,291
-3,116
1,509
6,939
Cash, cash equivalents, and restricted cash at beginning of the period
26,046
29,162
27,653
17,868
Cash, cash equivalents, and restricted cash at end of the period
23,755
26,046
29,162
27,653
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of investments
$26,964K
(-70.40%↓ Y/Y)
Proceeds from issuance of
common stock, net
$9,075K
Net cash provided by
investing activities
$18,260K
(-49.09%↓ Y/Y)
Net cash provided by
financing activities
$9,075K
Canceled cashflow
$8,704K
Net (decrease)
increase in cash, cash...
-$2,291K
(-180.50%↓ Y/Y)
Canceled cashflow
$27,335K
Accounts payable
$4,810K
(1044.99%↑ Y/Y)
Stock-based compensation
expense
$1,806K
(-44.89%↓ Y/Y)
Prepaid expenses and
other current assets
-$150K
(-106.47%↓ Y/Y)
Operating right-of-use
assets and operating...
-$78K
Depreciation expense
$51K
(-61.94%↓ Y/Y)
Other
-$10K
(-103.46%↓ Y/Y)
Purchases of investments
$8,698K
(-84.25%↓ Y/Y)
Purchases of property and
equipment
$6K
Net cash used in
operating activities
-$29,626K
(10.28%↑ Y/Y)
Canceled cashflow
$6,905K
Net loss
-$35,037K
(-1.15%↓ Y/Y)
Accrued expenses
-$1,268K
(-157.01%↓ Y/Y)
Net amortization of
premiums and discounts on...
$226K
(-63.78%↓ Y/Y)
Buy us a coffee
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)